SCHEMBL12366186

SCHEMBL12366186

CC1C=C(c2cc(Cl)c(F)cc2F)c2cc(C(=O)O)ccc2O1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 1/20 0.41
TSHR P16473 1/20 0.35
AKR1B1 P15121 2/20 0.34
MAPK1 P28482 2/20 0.33
LMNA P02545 1/20 0.33
HTT P42858 1/20 0.33
RAB9A P51151 1/20 0.33
TAS1R3 Q7RTX0 1/20 0.33
TAS1R1 Q7RTX1 1/20 0.33
TAS1R2 Q8TE23 1/20 0.33
DPP4 P27487 1/20 0.33
NOTUM Q6P988 1/20 0.33
PDK1 Q15118 1/20 0.32
PDK2 Q15119 1/20 0.32
PDK3 Q15120 1/20 0.32
PDK4 Q16654 1/20 0.32
TTR P02766 1/20 0.32
ALDH1A1 P00352 1/20 0.32
MRGPRX4 Q96LA9 1/20 0.32
CA12 O43570 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12366182 0.90 TDP1 (0.42) TDP1TSHRAKR1B1MAPK1LMNA
SCHEMBL12366180 0.87 MEN1 (0.40) TSHRRAB9APDK1PDK2PDK3
SCHEMBL12366031 0.87 TDP1 (0.39) TDP1TSHRAKR1B1MAPK1LMNA
SCHEMBL12366009 0.86 SRD5A2 (0.40) TDP1TSHRTTRMRGPRX4MCL1
SCHEMBL12366603 0.85 HTR5A (0.40)
SCHEMBL12366177 0.83 TDP1 (0.39) TDP1TSHRAKR1B1TTRRARB
SCHEMBL12365914 0.83 KDM4A (0.40) TDP1AKR1B1MAPK1LMNAHTT
SCHEMBL12366145 0.83 TDP1 (0.40) TDP1AKR1B1MAPK1LMNAHTT
SCHEMBL12366147 0.82 KMO (0.39) TDP1TSHRNOTUMTTRMRGPRX4
SCHEMBL12365573 0.82 TDP1 (0.39) TDP1TSHRMAPK1LMNAHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110207729-A1 BICYCLIC ACYLGUANIDINE DERIVATIVE ASTELLAS PHARMA INC. (JP) 2011-08-25 US disclosed
US-20110207729-A1 BICYCLIC ACYLGUANIDINE DERIVATIVE ASTELLAS PHARMA INC. (JP) 2011-08-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110207729-A1 BICYCLIC ACYLGUANIDINE DERIVATIVE HTR5A, HTR2A, HTR1E TDP1 378/4885TSHR 821/4885AKR1B1 740/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.